{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:30:12Z","timestamp":1789432212445,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Invasive fungal disease (IFD) can be a severe treatment complication in patients with myeloid malignancies, but current risk models do not incorporate disease-specific factors, such as somatic gene mutations. Germline GATA2 deficiency is associated with a susceptibility to IFD. To determine whether myeloid gene mutations were associated with IFD risk, we identified 2 complementary cohorts of patients with myeloid malignancy, based on (1) the diagnosis of invasive aspergillosis (IA), or (2) the presence of GATA2 mutations identified during standard clinical sequencing. We found somatic GATA2 mutations in 5 of 27 consecutive patients who had myeloid malignancy and developed IA. Among 51 consecutive patients with GATA2 mutations identified in the evaluation of myeloid malignancy, we found that IFD was diagnosed and treated in 21 (41%), all of whom had received chemotherapy or had undergone an allogeneic stem cell transplant. Pulmonary infections and disseminated candidiasis were most common. The 90-day mortality was 52% among patients with IFD. Our results indicate that patients with somatic GATA2 mutations are a vulnerable subgroup of patients with myeloid malignancy who have high risk for treatment-associated IFD and suggest that a focused approach to antifungal prophylaxis be considered.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002854","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T16:36:13Z","timestamp":1609432573000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-3981","authenticated-orcid":false,"given":"Rahul S.","family":"Vedula","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-2063","authenticated-orcid":false,"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Ronayne","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, University of Minnesota Medical School, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakiotis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Warren Alpert Medical School, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8734","authenticated-orcid":false,"given":"Francisco M.","family":"Marty","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-6546","authenticated-orcid":false,"given":"Tyler D.","family":"Bold","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, University of Minnesota Medical School, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"issue":"22","key":"2020123116360556700_B1","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020123116360556700_B2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2020123116360556700_B3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020123116360556700_B4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.13317","article-title":"Haematopoietic and immune defects associated with GATA2 mutation","volume":"169","author":"Collin","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2020123116360556700_B5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ng.923","article-title":"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)","volume":"43","author":"Ostergaard","year":"2011","journal-title":"Nat Genet"},{"issue":"10","key":"2020123116360556700_B6","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","article-title":"Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome","volume":"118","author":"Hsu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020123116360556700_B7","doi-asserted-by":"crossref","first-page":"e1003940","DOI":"10.1371\/journal.ppat.1003940","article-title":"Inflammatory monocytes orchestrate innate antifungal immunity in the lung","volume":"10","author":"Espinosa","year":"2014","journal-title":"PLoS Pathog"},{"issue":"4","key":"2020123116360556700_B8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/QCO.0000000000000381","article-title":"Immune responses to invasive aspergillosis: new understanding and therapeutic opportunities","volume":"30","author":"Hohl","year":"2017","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"2020123116360556700_B9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1080\/10428194.2018.1551535","article-title":"Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype","volume":"60","author":"Alfayez","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2020123116360556700_B10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/bloodadvances.2017012617","article-title":"Can somatic GATA2 mutation mimic germ line GATA2 mutation?","volume":"2","author":"Sekhar","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2020123116360556700_B11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"issue":"6","key":"2020123116360556700_B12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020123116360556700_B13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/myc.13013","article-title":"Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis","volume":"63","author":"Cheng","year":"2020","journal-title":"Mycoses"},{"issue":"6","key":"2020123116360556700_B14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2020123116360556700_B15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/mmy\/myu036","article-title":"Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"52","author":"van de Peppel","year":"2014","journal-title":"Med Mycol"},{"issue":"6","key":"2020123116360556700_B16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2009.012633","article-title":"Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia","volume":"95","author":"Chabrol","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"2020123116360556700_B17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/leu.2012.174","article-title":"GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis","volume":"27","author":"Fasan","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2020123116360556700_B18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12890-015-0083-2","article-title":"GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders","volume":"15","author":"Griese","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"4","key":"2020123116360556700_B19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ajh.23661","article-title":"Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes","volume":"89","author":"Buckley","year":"2014","journal-title":"Am J Hematol"},{"issue":"9","key":"2020123116360556700_B20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.21776","article-title":"Invasive fungal disease in patients treated for newly diagnosed acute leukemia","volume":"85","author":"Hammond","year":"2010","journal-title":"Am J Hematol"},{"issue":"7","key":"2020123116360556700_B21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents","volume":"95","author":"Kim","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2020123116360556700_B22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12879-015-1329-6","article-title":"Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study","volume":"15","author":"Harrison","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2020123116360556700_B23","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2013a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"issue":"4","key":"2020123116360556700_B24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"436","key":"2020123116360556700_B25","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"issue":"26","key":"2020123116360556700_B26","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2020123116360556700_B27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/1\/54\/1796138\/advancesadv2020002854.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/1\/54\/1796138\/advancesadv2020002854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T16:36:46Z","timestamp":1609432606000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/1\/54\/474810\/Somatic-GATA2-mutations-define-a-subgroup-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002854","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}